- Product
- Gout drug allopurinol side effect alert
- by Kang, Shin-Kook Nov 20, 2024 06:08am
- As reports of adverse reactions to allopurinol, a drug prescribed for gout, continue to mount, health authorities are calling for genetic testing of patients before prescribing it to prevent side effects. According to medical and pharmaceutical associations on the 19th, the NMC Adverse Drug Reaction&160;Committee recently reviewed applicatio
- Company
- ‘Use of Prevenar 20 will rise to address the unmet need'
- by Son, Hyung Min Nov 20, 2024 06:08am
- Prevenar 20 has become the pneumococcal vaccine that covers the most serotypes in Korea. Experts believe that its use will increase to address the unmet need for a treatment that protects against serotypes not targeted by existing vaccines. Pfizer Korea held a press conference at the Lotte Hotel in Jung-gu, Seoul on the 19th to celebrate
- Policy
- Stelara biosimilars face increasing competition
- by Lee, Tak-Sun Nov 20, 2024 06:08am
- Competition among biosimilars referencing Stelara (ustekinumab) for treating autoimmune diseases heats up. Samsung Bioepis added its biosimilar to the reimbursement list in July, and Celltrion added theirs in September. Since Celltrion is set to cut the price starting next month, attention has been drawn to future competition. According
- Company
- Drug switching policy for atopic dermatitis fails to address
- by Whang, byung-woo Nov 20, 2024 06:08am
- A discussion has been advancing to allow drug switching between a biological agent and a JAK inhibitor for treating atopic dermatitis (hereafter referred to as atopy), and there have been further suggestions for the revision. The Health Insurance Review and Assessment Service (HIRA) has already established reimbursement criteria, but concerns
- Company
- Returned out-licensing, Daewoong's autoimmune disease drug
- by Son, Hyung Min Nov 19, 2024 06:13am
- Daewoong Pharmaceutical's new drug candidate, 'DWP213388,' for the treatment of autoimmune diseases is set to return after a year and a half. DWP213388, a new drug candidate developed as the First-in-Class, has entered the Phase 1 clinical trial. According to the Financial Supervisory Service (FSS) on November 16, Daewoong Pharmaceutical
- Company
- Three months after Pluvicto launch
- by Moon, sung-ho Nov 19, 2024 06:13am
- Novartis Korea's prostate cancer treatment, Pluvicto, which has garnered attention since its approval by the Ministry of Food and Drug Safety (MFDS), has now been administered to Korean patients for three months. Pluvicto is a blockbuster drug that generated over KRW 1 trillion in global sales last year and is recognized as a product initiati
- Company
- Imfinzi passes first step to reimb in KOR… key is the price
- by Whang, byung-woo Nov 19, 2024 06:13am
- With the reimbursement standard set for the immuno-oncology drug Imfinzi (durvalumab), which is under review for reimbursement extensions, how the discussions will develop thereafter is gaining attention. Although the first step has been taken, attention is being paid to the future process as the matter was mentioned during the National Assem
- Policy
- Samil voluntarily cuts price of its Vemlino to lowest price
- by Lee, Tak-Sun Nov 19, 2024 06:13am
- Samil Pharm is voluntarily reducing the price of its hepatitis B drug Vemlino (Tenofovir Alafenamide Hemimalate). This will render the drug to be the lowest-priced drug among tenofovir alafenamide drugs, increasing its price competitiveness. According to industry sources on the 18th, the price of Vemlino will be reduced from KRW 2,425 t
- Company
- Mounjaro aims for 'diabetes·obesity' synergy
- by Whang, byung-woo Nov 19, 2024 06:12am
- Eli Lily's Mounjaro (tirzepatide), the first once-weekly GIP·GLP-1 receptor agonist, will enter the market with its diabetes and obesity indications. Unlike already launched Wegovy (semaglutide), Mounjaro has two indications: diabetes and obesity. Experts anticipate that Mounjaro's sales strategy will be focused on diabetes treatment a
- Company
- Academia pushes for Tagrisso’s reimbursement expansion
- by Moon, sung-ho Nov 19, 2024 06:12am
- Less than a year after AstraZeneca's lung cancer drug Tagrisso (osimertinib) was granted expanded reimbursement coverage, another round of discussions on its further expansion has begun, drawing attention to its background. As the expansion request came from the medical community, not pharmaceutical companies, it will be interesting to see i
